Rallybio 求取股东授权进行反向股票分割，以维持纳斯达克上市

summarizeSummary

Rallybio Corp is proposing a reverse stock split to address its non-compliance with Nasdaq's minimum bid price requirement. The company received a delisting notice in February 2025 and is in its second 180-day compliance period, which expires in February 2026. While a reverse split can temporarily boost the share price to meet listing standards, it does not resolve the underlying operational or financial issues that led to the low stock price. The wide range of potential ratios (1-for-5 to 1-for-20) indicates the severity of the challenge. Investors should view this as a critical measure to maintain market access, but also as a strong signal of the company's distressed financial position and the potential for future dilution from the increased pool of authorized but unissued shares.

check_boxKey Events

• 反向股分裂提议

  股东将投票通过修订公司章程，进行反向股分，分次比率为1股5股至1股20股，由董事会决定。

• 纳斯达克上市合规

  反向股分割的主要目的在于恢复并维持与纳斯达克的 $1.00 最低收盘价要求的遵守，以避免被除牌。

• 摘牌通知收到

  拉利比奥于2025年2月24日收到纳斯达克的退市决定函，并且有至2026年2月23日的时间机会重新恢复符合退市标准。

• 增加授权股份

  该逆向股分将显著增加已授权但未发行的股份数量，提供了为广泛的公司目的，包括股权补偿计划，提供灵活性。

auto_awesomeAnalysis

Rallybio Corp is proposing a reverse stock split to address its non-compliance with Nasdaq's minimum bid price requirement. The company received a delisting notice in February 2025 and is in its second 180-day compliance period, which expires in February 2026. While a reverse split can temporarily boost the share price to meet listing standards, it does not resolve the underlying operational or financial issues that led to the low stock price. The wide range of potential ratios (1-for-5 to 1-for-20) indicates the severity of the challenge. Investors should view this as a critical measure to maintain market access, but also as a strong signal of the company's distressed financial position and the potential for future dilution from the increased pool of authorized but unissued shares.